These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1181 related articles for article (PubMed ID: 25449570)

  • 41. Molecular architecture of human prion protein amyloid: a parallel, in-register beta-structure.
    Cobb NJ; Sönnichsen FD; McHaourab H; Surewicz WK
    Proc Natl Acad Sci U S A; 2007 Nov; 104(48):18946-51. PubMed ID: 18025469
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Application of yeast to studying amyloid and prion diseases.
    Chernoff YO; Grizel AV; Rubel AA; Zelinsky AA; Chandramowlishwaran P; Chernova TA
    Adv Genet; 2020; 105():293-380. PubMed ID: 32560789
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prion assemblies: structural heterogeneity, mechanisms of formation, and role in species barrier.
    Igel A; Fornara B; Rezaei H; Béringue V
    Cell Tissue Res; 2023 Apr; 392(1):149-166. PubMed ID: 36399162
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prion agent diversity and species barrier.
    Béringue V; Vilotte JL; Laude H
    Vet Res; 2008; 39(4):47. PubMed ID: 18519020
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant Mammalian Prions: The "Correctly" Misfolded Prion Protein Conformers.
    Ma J; Zhang J; Yan R
    Viruses; 2022 Aug; 14(9):. PubMed ID: 36146746
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Attempt to Untangle the Prion-Like Misfolding Mechanism for Neurodegenerative Diseases.
    Sarnataro D
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30304819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epigenetic Changes in Prion and Prion-like Neurodegenerative Diseases: Recent Advances, Potential as Biomarkers, and Future Perspectives.
    Hernaiz A; Toivonen JM; Bolea R; Martín-Burriel I
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293477
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins.
    Silva JL; Vieira TC; Gomes MP; Bom AP; Lima LM; Freitas MS; Ishimaru D; Cordeiro Y; Foguel D
    Acc Chem Res; 2010 Feb; 43(2):271-9. PubMed ID: 19817406
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Methods for conversion of prion protein into amyloid fibrils.
    Breydo L; Makarava N; Baskakov IV
    Methods Mol Biol; 2008; 459():105-15. PubMed ID: 18576151
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The prion-like nature of amyotrophic lateral sclerosis.
    McAlary L; Yerbury JJ; Cashman NR
    Prog Mol Biol Transl Sci; 2020; 175():261-296. PubMed ID: 32958236
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nucleic acid and prion protein interaction produces spherical amyloids which can function in vivo as coats of spongiform encephalopathy agent.
    Nandi PK; Nicole JC
    J Mol Biol; 2004 Nov; 344(3):827-37. PubMed ID: 15533448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neurodegenerative diseases: expanding the prion concept.
    Walker LC; Jucker M
    Annu Rev Neurosci; 2015 Jul; 38():87-103. PubMed ID: 25840008
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The highways and byways of prion protein trafficking.
    Campana V; Sarnataro D; Zurzolo C
    Trends Cell Biol; 2005 Feb; 15(2):102-11. PubMed ID: 15695097
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cross-seeding of prions by aggregated α-synuclein leads to transmissible spongiform encephalopathy.
    Katorcha E; Makarava N; Lee YJ; Lindberg I; Monteiro MJ; Kovacs GG; Baskakov IV
    PLoS Pathog; 2017 Aug; 13(8):e1006563. PubMed ID: 28797122
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prion and prion-like diseases in animals.
    Aguilar-Calvo P; García C; Espinosa JC; Andreoletti O; Torres JM
    Virus Res; 2015 Sep; 207():82-93. PubMed ID: 25444937
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Heterogeneity and Architecture of Pathological Prion Protein Assemblies: Time to Revisit the Molecular Basis of the Prion Replication Process?
    Igel-Egalon A; Bohl J; Moudjou M; Herzog L; Reine F; Rezaei H; Béringue V
    Viruses; 2019 May; 11(5):. PubMed ID: 31083283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecular dynamics studies on the NMR and X-ray structures of rabbit prion proteins.
    Zhang J; Zhang Y
    J Theor Biol; 2014 Feb; 342():70-82. PubMed ID: 24184221
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interactions of recombinant prions with compounds of therapeutical significance.
    Georgieva D; Schwark D; von Bergen M; Redecke L; Genov N; Betzel C
    Biochem Biophys Res Commun; 2006 Jun; 344(2):463-70. PubMed ID: 16630566
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cellular prion protein mediates toxic signaling of amyloid beta.
    Resenberger UK; Winklhofer KF; Tatzelt J
    Neurodegener Dis; 2012; 10(1-4):298-300. PubMed ID: 22156337
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structural attributes of mammalian prion infectivity: Insights from studies with synthetic prions.
    Li Q; Wang F; Xiao X; Kim C; Bohon J; Kiselar J; Safar JG; Ma J; Surewicz WK
    J Biol Chem; 2018 Nov; 293(48):18494-18503. PubMed ID: 30275016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 60.